0000899243-21-010458.txt : 20210308 0000899243-21-010458.hdr.sgml : 20210308 20210308194339 ACCESSION NUMBER: 0000899243-21-010458 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210225 FILED AS OF DATE: 20210308 DATE AS OF CHANGE: 20210308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bylund James CENTRAL INDEX KEY: 0001849642 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 21723636 MAIL ADDRESS: STREET 1: C/O REPLIGEN CORPORATION STREET 2: 41 SYON ST. BLDG. SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-02-25 0 0000730272 REPLIGEN CORP RGEN 0001849642 Bylund James C/O REPLIGEN CORPORATION 41 SEYON ST., BLDG 1, STE 100 WALTHAM MA 02453 0 1 0 0 SVP, Global Operations & IT Common Stock 5000 D Common Stock 1684 D Stock Option (Right to Buy) 94.33 2030-04-01 Common Stock 5300 D Stock Option (Right to Buy) 94.33 2030-04-01 Common Stock 4700 D Stock Option (Right to Buy) 207.07 2031-02-23 Common Stock 2033 D Mr. Bylund was awarded 5,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a five-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Mr. Bylund was awarded 1,684 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. This option shall vest in equal yearly installments over a five-year period beginning on 4/1/2021. This option shall vest in equal yearly installments over a three-year period beginning on 2/24/2022. Exhibit 24.1: Power of Attorney /s/ Christopher German, attorney-in-fact 2021-03-08 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

                               POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and
appoints each of Jon Snodgres, Christopher German and Kenneth O'Brien the true
and lawful attorney-in-fact and agent, with full power of substitution and
resubstitution, for the undersigned and in the undersigned's name, place and
stead, in any and all capacities (until revoked in writing) to execute for and
on behalf of the undersigned, in any and all of the undersigned's capacities,
any and all statements on Forms 3, 4 and 5 with respect to the undersigned's
holdings of and transactions in securities issued by Repligen Corporation (the
"Company") in accordance with Sections 16(a) of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), and any and all regulations promulgated
thereunder, and to file the same, with all exhibits thereto, and any other
documents in connection therewith, with the Securities and Exchange Commission,
and with any other entity when and if such is mandated by the Exchange Act or by
the By-laws of the Financial Industry Regulatory Authority, granting unto said
attorney-in-fact and agent full power and authority to do and perform each and
every act and thing requisite and necessary fully to all intents and purposes as
the undersigned might or could do in person thereby ratifying and confirming all
that said attorney-in-fact and agent, or his substitute or substitutes, may
lawfully do or cause to be done by virtue hereof.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of February 25, 2021.


                                      /s/ James Bylund
                                      ----------------------------------
                                      Name: James Bylund